Conference data in Cortellis

Cortellis Competitive Intelligence

The Cortellis editorial team cover more than 100 conferences every year. These include partnering meetings such as BIO, JP Morgan and scientific conferences like American Society of Clinical Oncology (ASCO) and Annual European Congress of Rheumatology. Conferences are an excellent source of new information as well as updates on drugs, deals, companies and related data. Information is added to Cortellis within a couple of days following the conference.

This guide explains how to access conference reports from different areas in *Cortellis Competitive Intelligence*.

1. Links for recent and upcoming conference are found on the *Home page* in the *News* tile.
   Like other reports in Cortellis, conference reports are indexed to make it easier for you to search and filter by date, indication or mechanism of action, for example.
   Forthcoming meetings include a link to the conference website for registration and other details whereas past meetings include a link for a conference report in Cortellis.

2. Posters presented in conferences are summarized under *Presentations* on the results page.

Conference data is available in Cortellis as reports and presentations

3. Highlights from lectures and oral presentations are available in *Reports* on the results page. Overnight reports are written and published in *Cortellis Competitive Intelligence* within 12-24 hours after the event.

Association for Research in Vision and Ophthalmology (ARVO) – 2021 Annual Meeting (Part II), OVERNIGHT REPORT, Virtual Meeting

REPORT

Croasdell G

gary.croasdell@clarivate.com; Clarivate, London, UK.

ABP-201 FOR ANGIOGENIC EYE DISEASES

Zsolt Ablonczy from Ora presented data for the tetravalent bispecific antibody against VEGF and angiopoietin-2 (ANG-2) ABP-201 (Abmed) in a laser-induced rat choroidal neovascularization (CNV) to assess its activity for treating angiogenetic eye pathologies. Brown-Norway rats were administered 5 microl intravitreal injections in the right eye of the antibody at either 0.0385 (low), 0.385 (mid) or 3.85 microg/microl (high) doses, vehicle or aflibercept (Eylea, 0.2 microg/microl) immediately following burning of 4 to 5 lesions of 200 micron, with day 7 and 15 fluorescein angiography and OCT assessment of lesion leakage and volume. Fluorescein angiography scores on day 7 showed a significant reduction in leakage compared to vehicle: 33, 35 and 37% for the respective doses (p<0.0002); this was also the case on day 15 (28, 33 and 36%; p<0.05); the effect was similar to aflibercept. The OCT assessment showed significant lesion volume reduction with all doses compared to vehicle at day 7 (27, 27 and 40%; p<0.01); day 15 results were significant for the mid and high doses (26 and 27%; p<0.05); all results were similar or improved over aflibercept. These data help support the use of ABP-201 as a treatment for angiogenic eye diseases.

Conference *Reports* and *Presentations* are linked to drugs, companies and other reports mentioned in the event to help you quickly navigate to related information and investigate further.

Identify new drugs and read important updates on existing drugs in Cortellis Conference reports

4. Conference reports are also listed on the *Sources* tab in drug, deals and clinical trials and other reports.

Click 'View full report' to navigate to conference report cited as a source

5. Conference reports can also be retrieved using *Quick search* at the top of the screen when searching for drug and company names as well as mechanism of actions and other indexed fields.

Conference reports can be searched by title, indication, mechanism of action, chemical structure and more

For more information contact Customer Service at **LS Product Support**